Search
Search Constraints
You searched for: Author/Creator Miller, Jacqueline M.Limit your search
- Miller, Jacqueline M. [remove] 15
- 615.372 11
- Vaccines -- Periodicals 11
- 618.929 4
- Communicable diseases in children -- Periodicals 4
- Infection in children -- Periodicals 4
- 95% CI 95 percent confidence interval -- ACIP Advisory Committee on Immunization Practices -- AE adverse event -- ATP according-to-protocol -- Coad co-administration treatment group who received MenACWY-TT+ DTaP at the fourth dose visit (15/18 months of age) -- DTaP combined diphtheria–tetanus–acellular pertussis vaccine -- DTaP-HBV-IPV combined diphtheria–tetanus–acellular pertussis–hepatitis B-inactivated poliovirus vaccine -- FHA filamentous hemagglutinin -- GMC geometric mean antibody concentrations -- Hib-MenCY-TT Meningococcal serogroup C and Y conjugate vaccine combined with Haemophilus influenzae type b conjugate vaccine -- Hib-TT Haemophilus influenzae type b conjugate vaccine -- IMD invasive meningococcal disease -- MenACWY-DT quadrivalent serogroups A, C, W-135 and Y conjugate vaccine with all serogroups conjugated to the diphtheria toxoid carrier protein -- MenACWY-CRM197 quadrivalent serogroups A, C, W-135 and Y conjugate vaccine with all serogroups conjugated to CRM-197 (mutant diphtheria toxoid) -- MenACWY-TT quadrivalent serogroups A, C, W-135 and Y conjugate vaccine with all serogroups conjugated to the tetanus toxoid carrier protein -- SAE serious adverse event -- PRN pertactin -- PRP polyribosylribitol phosphate -- PT pertussis toxin -- TT tetanus toxoid -- US United States 1
- 95% CI 95 percent confidence interval -- ACIP Advisory Committee on Immunization Practices -- AE adverse event -- ATP according-to-protocol -- Coad co-administration treatment group who received MenACWY-TT + DTaP at the fourth dose visit (15/18 months of age) -- DTaP combined diphtheria–tetanus–acellular pertussis vaccine -- DTaP–HBV–IPV combined diphtheria–tetanus–acellular pertussis–hepatitis B-inactivated poliovirus vaccine -- GMT geometric mean antibody titers -- Hib-MenCY-TT meningococcal serogroup C and Y conjugate vaccine combined with Haemophilus influenzae type b conjugate vaccine -- Hib-TT Haemophilus influenzae type b conjugate vaccine -- hSBA serum bactericidal activity using human complement source -- IMD invasive meningococcal disease -- MenACWY-DT quadrivalent serogroups A, C, W and Y conjugate vaccine with all serogroups conjugated to the diphtheria toxoid carrier protein -- MenACWY-CRM197 quadrivalent serogroups A, C, W and Y conjugate vaccine with all serogroups conjugated to CRM-197 (mutant diphtheria toxoid) -- MenACWY-TT quadrivalent serogroups A, C, W and Y conjugate vaccine with all serogroups conjugated to the tetanus toxoid carrier protein -- SAE serious adverse event -- PRN pertactin -- TT tetanus toxoid -- US United States 1
- ACIP Advisory Committee on Immunization Practices -- AE adverse event -- ATP according-to-protocol -- CI confidence interval -- GMC geometric mean concentration -- GMT geometric mean titer -- Hib Haemophilus influenzae type b -- HIV human immunodeficiency virus -- hSBA serum bactericidal activity assay using human complement -- MenACWY-TT quadrivalent serogroups A, C, W and Y conjugate vaccine using tetanus toxoid as carrier protein -- IU international units -- PS polysaccharides -- rSBA serum bactericidal activity assay using rabbit complement -- SAE serious adverse event -- TVC total vaccinated cohort -- US United States -- VRR vaccine response rate 1
- ATP according-to-protocol -- ACIP Advisory Committee on Immunization Practice -- AE adverse events -- AESI adverse event of specific interest -- CI confidence interval -- DTaP diphtheria-tetanus-acellular pertussis -- ELISA enzyme-linked immunosorbent assay -- GMC geometric mean concentration -- GMT geometric mean titer -- HBV hepatitis B virus -- Hib Haemophilus influenzae type b -- HRV human rotavirus vaccine -- IPV inactivated poliovirus -- LAR legally acceptable representative -- LL lower limit -- PCV pneumococcal conjugate vaccine -- PRP polyribosyl ribitolphosphate -- SAE serious adverse event -- TT tetanus toxoid -- TVC total vaccinated cohort -- URTI upper respiratory tract infection -- US United States 1
- Asplenia -- Neisseria meningitidis -- Meningococcal disease -- Meningococcal vaccine -- Immunogenicity -- Safety 1